Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients

Affiliations

• ¹ Sorbonne Université, INSERM, Pierre Louis Institute of Epidemiology and Public Health (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Medical Oncology, Pitié Salpêtrière Hospital, Paris, France; Sorbonne Université, INSERM, Pierre Louis Institute of Epidemiology and Public Health (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Infectious Diseases, Pitié Salpêtrière Hospital, Paris, France. Electronic address: romain.palich@aphp.fr.
• ² Sorbonne Université, INSERM, Pierre Louis Institute of Epidemiology and Public Health (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié Salpêtrière Hospital, Department of Medical Oncology, Institut Universitaire de Cancérologie (IUC), CLIP(2) Galilée, Paris, France.
• ³ Sorbonne Université, INSERM, Pierre Louis Institute of Epidemiology and Public Health (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Virology, Pitié Salpêtrière Hospital, Paris, France.
• ⁴ Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Medical Oncology, Tenon Hospital, Institut Universitaire de Cancérologie (IUC), CLIP(2) Galilée, Paris, France.
• ⁵ Sorbonne Université, INSERM, Pierre Louis Institute of Epidemiology and Public Health (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié Salpêtrière Hospital, Department of Oncology Radiotherapy, Institut Universitaire de Cancérologie (IUC), CLIP(2) Galilée, Paris, France.